Research analysts covering POMDOCTOR.
Recent press releases and 8-K filings for POM.
POMDOCTOR Expands Online Medical Insurance Integration
POM
New Projects/Investments
- POMDOCTOR LIMITED announced on February 4, 2026, a strategic initiative to integrate its online medical services platform with China's national and local coordinated medical insurance systems across major cities.
- This integration is expected to significantly expand the Company's market reach and enhance service offerings for partner internet hospitals, pharmacies, and patients, aligning with China's policy support for internet-based medical services.
- Building on over two years of successful medical insurance settlements in Guangzhou, POMDOCTOR plans to expand into other Greater Bay Area cities, including Foshan (Q1 2026), and major municipalities like Beijing, Shanghai, and Tianjin.
- The initiative enables patients to complete online consultations, receive digital prescriptions, and obtain near-real-time insurance reimbursement for home-delivered medications, leading to more accessible care and reduced financial burdens.
3 days ago
Pomdoctor Expands Medical Insurance Integration
POM
New Projects/Investments
- POMDOCTOR LIMITED announced a strategic initiative to deepen the integration of its online medical services platform with China's national and local coordinated medical insurance systems across major cities nationwide.
- This expansion leverages China's policy trajectory since 2018 promoting internet-based medical services and online medical insurance reimbursement.
- Pomdoctor has successfully supported medical insurance settlements in Guangzhou for over two years and plans to expand into other Greater Bay Area cities like Foshan (planned for Q1 2026), as well as Beijing, Shanghai, and other major regional centers.
- The integration will provide patients with more accessible care, allowing for online consultations, digital prescriptions, near-real-time insurance reimbursement, and home delivery of medications.
3 days ago
POMDOCTOR Limited Notified of Nasdaq Minimum Bid Price Deficiency
POM
Delisting/Listing Issues
- POMDOCTOR LIMITED received a Nasdaq Deficiency Letter on January 29, 2026, because its American depositary shares (ADSs) had a closing bid price below the US$1.00 minimum requirement for 33 consecutive business days.
- The company has a 180-calendar-day compliance period, until July 28, 2026, to regain compliance by achieving a closing bid price of at least US$1.00 for a minimum of ten consecutive business days.
- This Deficiency Letter does not currently affect the listing or trading of the company's ADSs on Nasdaq, nor does it impact its business operations.
5 days ago
POMDOCTOR Strengthens Strategic Partnerships for Internet Hospital Growth
POM
New Projects/Investments
Revenue Acceleration/Inflection
- POMDOCTOR LIMITED announced significant progress in strategic collaborations with pharmaceutical companies to accelerate the growth of its internet hospital business.
- These partnerships are a core component of its long-term strategy to expand online hospital operations and enhance overall profitability.
- The collaborations include sales and purchase agreements with several industry leaders, such as Jiangsu Haosoh Pharmaceutical Group Co., Ltd. and Eddingpharm (Suzhou) Co., Ltd..
- This strategy leverages China's rapidly expanding online drug sales market, which reached RMB 71.8 billion (approximately US$10.3 billion) in 2024, providing Pomdoctor with favorable purchase terms and expanding access to innovative products.
Jan 16, 2026, 2:08 PM
Pomdoctor Announces Strategic Pharmaceutical Partnerships to Drive Internet Hospital Growth
POM
New Projects/Investments
Revenue Acceleration/Inflection
- POMDOCTOR LIMITED announced significant progress in strategic collaborations with leading domestic pharmaceutical companies to accelerate the growth of its internet hospital business and enhance overall profitability.
- These partnerships, which include agreements with companies such as Jiangsu Haosoh Pharmaceutical Group Co., Ltd., enable Pomdoctor to introduce innovative and patented pharmaceutical products and secure favorable purchase discounts, rebates, and sales incentives.
- The strategy capitalizes on China's rapidly expanding online pharmaceutical sales market, which grew from RMB 19 billion in 2020 to RMB 71.8 billion (approximately US$10.3 billion) in 2024, reflecting a 39.4% compound annual growth rate.
- Pomdoctor views this supply-chain collaboration model as a core component of its long-term strategy, aiming to reduce intermediaries and improve efficiency, transparency, and accessibility across the pharmaceutical distribution value chain.
Jan 16, 2026, 2:00 PM
POMDOCTOR Announces First Half of Fiscal 2025 Unaudited Financial Results
POM
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- For the six months ended June 30, 2025, POMDOCTOR Limited reported net revenues of RMB174.5 million (US$24.4 million), a 16.2% increase from RMB150.2 million in the prior year period, primarily driven by an 83.2% growth in online-pharmacy businesses.
- Gross profit increased by 16.3% to RMB28.3 million (US$4.0 million) for the first half of fiscal 2025, with the gross profit margin remaining stable at 16.2%.
- The company's net loss widened to RMB19.9 million (US$2.8 million) for the six months ended June 30, 2025, compared to RMB14.0 million in the same period of 2024, with net loss per share at RMB11.45 (US$1.60).
- General and administrative expenses increased by 53.5% to RMB10.5 million (US$1.5 million), mainly due to consultancy and professional service fees related to the Company's initial public offering (IPO).
- POMDOCTOR completed its IPO in October 2025, raising US$23,000,016 in gross proceeds.
Dec 3, 2025, 9:15 PM
Pomdoctor Limited Announces First Half of Fiscal 2025 Unaudited Financial Results
POM
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Pomdoctor Limited reported net revenues of RMB174.5 million (US$24.4 million) for the six months ended June 30, 2025, marking a 16.2% increase compared to the same period in 2024, primarily driven by an 83.2% growth in online-pharmacy businesses.
- Gross profit for the first half of fiscal year 2025 increased by 16.3% to RMB28.3 million (US$4.0 million), with the gross profit margin remaining stable at 16.2%.
- The company recorded a net loss of RMB19.9 million (US$2.8 million) for the six months ended June 30, 2025, and a net loss per share of RMB11.45 (US$1.60).
- Pomdoctor Limited completed its Initial Public Offering (IPO) in October 2025, which provided additional capital resources and expanded opportunities for future growth.
Dec 3, 2025, 9:15 PM
POMDOCTOR Announces Full Exercise of Over-Allotment Option
POM
- POMDOCTOR LIMITED announced that the underwriter of its initial public offering (IPO) fully exercised its over-allotment option to purchase an additional 750,000 American Depositary Shares (ADSs) at a public offering price of $4.00 per ADS.
- The over-allotment option closing date was October 10, 2025.
- Gross proceeds to the company from the offering, including funds from the prior closing and the over-allotment option, totaled $23,000,016 before deducting underwriting discounts and other related expenses.
- The company's ADSs began trading on the Nasdaq Global Market on October 8, 2025, under the ticker symbol "POM".
Oct 10, 2025, 9:15 PM
POMDOCTOR Announces Closing of Initial Public Offering
POM
New Projects/Investments
- POMDOCTOR LIMITED (Nasdaq: POM) announced the closing of its initial public offering (IPO) on October 9, 2025.
- The Company offered 5,000,004 American Depositary Shares (ADSs) at a public offering price of US$4.00 per ADS.
- This offering generated aggregate gross proceeds of approximately US$20.0 million for the Company.
- The ADSs began trading on the Nasdaq Global Market under the ticker symbol "POM" on October 8, 2025.
- POMDOCTOR is a leading online medical services platform for chronic diseases in China, ranking sixth in China's Internet hospital market based on the number of contracted doctors in 2022.
Oct 9, 2025, 8:05 PM
POMDOCTOR LIMITED Prices Initial Public Offering
POM
Delisting/Listing Issues
- POMDOCTOR LIMITED announced the pricing of its Initial Public Offering (IPO) of 5,000,004 American Depositary Shares (ADSs) at a public offering price of US$4.00 per ADS.
- The company expects to receive approximately US$20.0 million in aggregate gross proceeds from the Offering.
- The ADSs have been approved for listing on the Nasdaq Global Market and are expected to commence trading on October 8, 2025, under the ticker symbol "POM".
- The Offering is expected to close on or about October 9, 2025, with Joseph Stone Capital, LLC acting as the underwriter.
Oct 8, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more